Watermark Group

Formerly active as a development-stage company focused on developing and commercializing rapid, multiplex PCR-based diagnostic tests for Zika virus and related mosquito-borne flaviviruses and alphaviruses, using patented Co-Dx™ technology licensed from a parent company. The company was a shell company at formation and transitioned into diagnostic biotech operations in late 2016. The company intended to market tests in both developed and developing nations, with an initial focus on regions affected by Zika outbreaks. No public clinical trial results or regulatory approvals were disclosed; operations appear to have ceased or transformed following company name change to Zika Diagnostics, Inc.